|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Matinas BioPharma Holdings, Inc.
| | | Phone: | (908) 443-1860 | Year Established: | 2011 | Ticker: | MTNB | Exchange: | NYSE | Main Contact: | Jerome D. Jabbour, CEO & Co-Founder | | Other Contacts: | Raphael J. Mannino, Ph.D., Senior VP & CTO Gary Gaglione, CPA, VP & Acting CFO Abdel A. Fawzy, Ph.D., Executive VP, Pharmaceutical & Supply Chain Development George Bobotas, Ph.D., Executive VP & CSO
| | Company Description | Matinas BioPharma is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel lipid-based pharmaceutical products for the treatment of infective diseases and cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. Recent additions to its product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. | |
|
|
|
|
|